Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin

NCT00086632 is registered in ClinicalTrials.gov with Unither Pharmaceuticals as lead sponsor.

NCT NCT00086632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin
Lead sponsor
Unither Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2004
Completion date
December 31, 2007
Enrollment
40
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer